The Epithelial Cell Adhesion Molecule (Ep-CAM) as a Morphoregulatory Molecule Is a Tool in Surgical Pathology

American Journal of Pathology

Volumn 163, Issue 6, 2003, Pages 2139-2148

  Winter, Manon J ^a   Nagtegaal, Iris D ^b   Van Krieken, J Han J M ^b   Litvinov, Sergey V ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Pickcell Laboratories   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CELL ADHESION MOLECULE; HERMES ANTIGEN; INTEGRIN; TUMOR ANTIGEN;

BLADDER EPITHELIUM; BREAST EPITHELIUM; CELL COMMUNICATION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLON MUCOSA; DISEASE COURSE; ESOPHAGUS MUCOSA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY EPITHELIUM; LIVER; LUNG ALVEOLUS EPITHELIUM; MOUTH MUCOSA; NONHUMAN; OVARY; PANCREAS; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN EPITHELIUM; STOMACH EPITHELIUM; TESTIS; TISSUE DISTRIBUTION; TUMOR CELL; UTERINE CERVIX EPITHELIUM;

EID: 0345275965     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63570-5     Document Type: Review

References (81)

1. Gumbiner BM: Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996, 84:345-357
2. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997, 183:404-411
3. Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F, Cornelisse CJ, Peterse JL, van de Vijver MJ: E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997, 76:1131-1133
4. Bracke ME, Van Roy FM, Mareel MM: The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996, 213:123-161
5. Berx G, Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumourigenesis and malignant progression. Breast Cancer Res 2001, 3:289-293
6. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Caldas C: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001, 344:1904-1909
7. Han AC, Soler AP, Knudsen KA, Salazar H: Distinct cadherin profiles in special variant carcinomas and other tumours of the breast. Hum Pathol 1999, 9:1035-1039
8. Perez MS, Walker LE: Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Immunol 1989, 142: 3662-3667
9. Strnad J, Hamilton AE, Beavers LS, Gamboa GC, Apelgren LD, Taber LD, Sportsman JR, Bumol TF, Sharp JD, Gadski RA: Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 1989, 49:314-317
10. Simon B, Podolsky DK, Moldenhauer G, Isselbacher KJ, Gattoni-Celli S, Brand SJ: Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci 1990, 87:2755-2759
11. Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H, Linnenbach AJ: Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci 1990, 87:3542-3546
12. Balzar M, Bakker HAM, Briaire-de Bruijn IH, Fleuren GJ, Warnaar SO, Litvinov SV: Cytoplasmic tail of the intercellular adhesion function of the epithelial adhesion molecule (Ep-CAM). Mol Cell Biol 1998, 18: 4833-4843
13. Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, Druck T, Huebner K: Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 1993, 13:1507-1515
14. Bergsagel PL, Victor-Kobrin C, Timblin CR, Trepel J, Kuehl WM: A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. J Immunol 1992, 148:590-596
15. Litvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994, 125:437-446
16. Litvinov SV, Bakker HAM, Gourevitch MM, Velders MP, Warnaar SO: Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994, 2:417-428
17. De Boer CJ, Van Dorst E, Van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ, Litvinov SV: Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol 1999, 155:505-515
18. Litvinov SV, Balzar M, Winter MJ, Bakker HAM, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Warnaar SO: Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997, 139:1337-1348
19. Winter MJ, Nagelkerken B, Mertens AEE, Rees-Bakker HAM, Briaire-de Bruijn IH, Litvinov SV: Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 2003, 285:50-58
20. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788-1794
21. Litvinov SV, van Driel W, Van Rhijn CM, Bakker HAM, Van Krieken JJM, Fleuren GJ, Warnaar SO: Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996, 148:865-875
22. High AS, Robinson PA, Klein CE: Increased expression of a 38kD cell-surface glycoprotein MH99 (KS 1/4) in oral mucosal dysplasias. J Oral Pathol Med 1996, 25:10-13
23. Takes RP, Baatenburg-de Jong RJ, Wijffels K, Schuuring E, Litvinov SV, Hermans J, Van Krieken JJM: Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. J Pathol 2001, 194:298-302
24. Chaubal S, Wollenberg B, Kastenbauer E, Zeidler R: Ep-CAM-a marker for the detection of disseminated tumor cells in patients suffering from SCCHN. Anticancer Res 1999, 19:2237-2242
25. Momburg F, Moldenhauer G, Haemmerling GJ, Moiler P: Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987, 47:2883-2891
26. Kumble S, Omary MB, Fajardo LF, Triadafilopoulos G: Multifocal heterogeneity in villin and Ep-CAM expression in Barret's esophagus. Int J Cancer 1996, 66:48-54
27. Watanabe R, Johzaki H, Iwasaki H, Kikuchi M, Ikeda S: A new tumor-associated antigen defined by a monoclonal antibody directed to gastric adenocarcinoma. Cancer 1993, 71:2439-2447
28. Songun I, Hermans J, Van de Velde CJH, Pals ST, Verspaget HW, Vis AN, Menon AG, Litvinov SV, Van Krieken JJM: Expression of oncoproteins and eosinophilic and lymphocytis infiltrates can be used as prognostic factors in gastric cancer. Br J Cancer 1996, 74:1783-1788
29. Songun I, Litvinov SV, Van de Velde CJH, Pals ST, Hermans J, Van Krieken JJM: Loss of Ep-CAM and CD44v6 (VFF18) predict survival in patients with gastric cancer: prognostic value for early stage. Thesis. Prognostic factors in gastric cancer. 1997, pp 97-106
30. Balzar M, Prins FA, Bakker HAM, Fleuren GJ, Warnaar SO, Litvinov SV: The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 1999, 246:108-121
31. Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D'Emilia JC, Herlyn M, Schlom J, Gottlieb LS: Expression of colorectal carcinoma-associated antigens in colonic polyps. J Surg Res 1993, 55:249-255
32. Packeisen J, Kaup-Franzen C, Knieriem HJ: Detection of surface antigen 17-1A in breast and colorectal cancer. Hybridoma 1999, 18:37-40
33. Staib L, Birebent B, Somasundaram R, Purev E, Braumuller H, Leeser C, Kuttner N, Li W, Zhu D, Diao J, Wunner W, Speicher D, Beger HG, Song H, Herlyn D: Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001, 92:79-87
34. Haller DG: Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer. Semin Oncol 2001, 28(Suppl 1):25-30
35. De Boer CJ, Van Krieken JH, Janssen-van Rhijn CM, Litvinov SV: Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999, 188:201-206
36. Sansonno D, Dammacco F: Expression and distribution of a human colon-carcinoma-associated antigen in normal and diseased liver tissue. Pathobiology 1993, 61:193-196
37. Porcell AI, De Young BR, Proca DM, Frankel WL: Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: mOC31 compares favorably with other putative markers. Mod Pathol 2000, 13:773-778
38. Proca DM, Niemann TH, Porcell AI, DeYoung BR: MOC31 immunoreactivity in proimary and metastatic carcinoma of the liver. Report findings and review of other utilized markers. Appl Immunohistochem Mol Morphol 2000, 8:120-125
39. Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A, Ptasznik A, Inverardi L, Ricordi C, Deerinck T, Ellisman M, Reisfeld RA, Hayek A: KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 1998, 140:1519-1534
40. Nolan LP, Heatley MK: The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol 2001, 20:155-159
41. Tomita Y, Arakawa F, Hirose Y, Liao S, Khare PD, Kuroki M, Yamamoto T, Ariyoshi A, Kuroki M: Carcinoma-associated antigens MK-1 and CEA in urological cancers. Anticancer Res 2000, 20:793-798
42. Zorzos J, Zizi A, Bakiras A, Pectasidis D, Skarlos DV, Zorzos H, Elemenoglou J, Likourinas M: Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Eur Urol 1995, 28:251-254
43. Kommoss F, Oliva E, Bitinger F, Kirkpatrick CJ, Amin MB, Bhan AK, Young RH, Scully RE: Inhibin-α, CD99, HEA125, FLAP and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol 2000, 31:1055-1061
44. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE: Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999, 162:1462-1466
45. MacDougall JR, Marisan LM: Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes. J Cell Sci 2000, 113:409-423
46. Balzar M, De Boer CJ, Breuer M, Warnaar SO Fleuren GJ, Litvinov SV: Ectopic Ep-CAM induces ductal morphogenesis and hyperplasia in mammary glands. 2001. Thesis. The biology of the epithelial cell adhesion molecule 2001, pp 128-147
47. Courtney SP, Williams S, Mansel RE: Monoclonal antibody 323/A3: a marker for the presence of breast carcinoma. Cancer Lett 1991, 57:115-119
48. Spizzo G, Obrist P, Ensinger C, Theurl I, Duenser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G: Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer 2002, 98:883-888
49. Ward BG, Lowe DG, Shepherd JH: Patterns of expression of a tumor associated antigen, defined by the monoclonal antibody HMFG2, in human epithelial ovarian carcinoma. Comparison with expression of the HMFG1, AUA1 and F36/22 antigens. Cancer 1987, 60:787-793
50. Cherchi PL, Marras V, Capobianco G, Ambrosini G, Piga M, Fadda GM, Dessole S: Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. Eur J Gynaecol Oncol 2001, 12:433-435
51. Kasper M, Behrens J, Schuh D, Muller M: Distribution of E-cadherin and Ep-CAM in the human lung during development and after injury. Histochem Cell Biol 1995, 103:281-286
52. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE: The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 2000, 31:482-487
53. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, Grizzle WE: The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000, 31:1068-1073
54. Gonzalez-Lois C, Ballestin C, Sotelo MT, Lopez-Rios F, Garcia-Prats MD, Villena V: Combined use of novel epithelial (MOC31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma of the pleura. Histopathology 2001, 38:528-534
55. Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K: Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999, 17:19-24
56. Tsubura A, Senzaki H, Sasaki M, Hilgers J, Morii S: Immunohistochemical demonstration of breast derived and/or carcinoma associated glycoproteins in normal skin appendages and their tumors. J Cutan Pathol 1992, 19:73-79
57. Tellechea O, Reis JP, Domingues JC, Baptista AP: Monoclonal antibody Ber-EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol 1993, 15:452-455
58. Klein CE, Cordon-Cardo C, Soehnchen R, Cote RJ, Oettgen HF, Eisinger M, Old LJ: Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. J Invest Derm 1987, 89:510-516
59. Jimenez FJ, Burchette Jr JL, Grichnik JM, Hitchcock MG: Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms. Mod Pathol 1995, 8:854-858
60. Tope WD, Nowfar-Rad M, Kist DA: Ber-EP4 positive phenotype differentiates actinic keratosis from superficial basal cell carcinoma. Dermatol Surg 2000, 26:415-418
61. Beer TW, Shepherd P, Theaker JM: Ber-EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 2000, 37:218-223
62. Balzar M, Briaire-de Bruijn IH, Rees-Bakker HAM, Prins FA, Helfrich W, De Leij L, Riethmuller G, Alberti S, Warnaar SO, Fleuren GJ, Litvinov SV: Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol 2001, 21:2570-2580
63. Kist D, Perkins W, Christ S, Zachary CB: Anti-human epithelial antigen (Ber-EP4) helps define basal cell carcinoma masked by inflammation. Dermatol Surg 1997, 23:1067-1070
64. Sheibani K, Shin SS, Kezirian J, Weiss LM: Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991, 15:779-784
65. Friedman MT, Gentile P, Tarectecan A, Fuchs A: Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Arch Pathol Lab Med 1996, 120:959-966
66. Roberts F, Harper CM, Downie I, Burnett RA: Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001, 116:253-262
67. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR: Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002, 40:237-244
68. Robinson RJ, Royston D: Comparison of monoclonal antibodies AUA1 and Ber-EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathol 1993, 4:267-271
69. Durbin H, Rodrigues N, Bodmer WF: Further characterization, isolation and identification of the epithelial cell-surface antigen defined by monoclonal antibody AUA1. Int J Cancer 1990, 45:562-565
70. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H: Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990, 43:213-219
71. Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979, 76:1438-1452
72. Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M, Kalland T: Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 1993, 268:24232-24241
73. Quak JJ, Schrijvers HG, Brakkee JG, Davis HD, Scheper RJ, Meijer CJ, Snow GB, Van Dongen GA: Expression and characterization of two differentiation antigens in human stratified squamous epithelia and carcinomas. Int J Cancer 1992, 50:507-513
74. Copper MP, Braakhuis BJ, de Vries N, van Dongen GA, Nauta JJ, Snow GB: A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. Cancer 1993, 71:825-830
75. Varki NM, Reisfeld RA, Walker LE: Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res 1984, 44:681-687
76. Schoen MP, Schoen M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE: Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4. Int J Cancer 1993, 55:988-995
77. Mattes MJ, Cairncross JG, Old LJ, Lloyd KO: Monoclonal antibodies to three widely distributed human cell surface antigens. Hybridoma 1983, 3:253-264
78. Myklebust AT, Beiske K, Pharo A, Davies CD, Aamdal S, Fodstad O: Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis. Br J Cancer Suppl 1991, 14:49-53
79. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002, 100:101-110
80. Helfrich W, Koning PW, The TH, De Leij L: Epitope mapping of SCLC-cluster-2 MAbs and generation of antibodies directed against new EGP-2 epitopes. Int J Cancer Suppl 1994, 8:64-69
81. Edwards DP, Grzyb KT, Dressier LG, Mansel RE, Zava DT, Sledge Jr GW, McGuire WL: Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986, 46:1306-1317